ALS Therapy Development Institute Signs Manufacturing Agreement with ALS Therapy Development Institute for High Quality Adenoviral Production

Published: Oct 17, 2007

CAMBRIDGE, Mass., Oct. 16 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) today announced it has signed an agreement with Microbix Biosystems Inc. of Toronto, Canada for the manufacturing of high quality adenoviral stocks to be tested in the mouse mode of Amyotrophic Lateral Sclerosis (ALS).

Back to news